openFDA
Cure8 regulatory brief
PYZCHIVA FDA label update (2026-07-09)
Medications
Ustekinumab
IL-12/23 inhibitor
Regulatory Update
Adult patients
Clinicians
Crohn's disease
Ulcerative colitis
Why This Matters
An FDA label update for PYZCHIVA adds/clarifies that this ustekinumab product is indicated for Crohn's disease and ulcerative colitis and reiterates safety monitoring steps (for infections and TB) that matter to people starting or taking the drug.
Who Should Pay Attention
Adults with moderately to severely active Crohn's disease or ulcerative colitis, clinicians who prescribe biologic therapies, and caregivers of pediatric patients on ustekinumab for psoriasis or psoriatic arthritis.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The FDA label for PYZCHIVA (an ustekinumab product) has been updated; the prescribing information lists indications including moderately to severely active Crohn's disease and ulcerative colitis in adults, plus psoriasis and psoriatic arthritis in adults and pediatric patients 6 years and older.
The label includes standard warnings and precautions for infections, tuberculosis screening before initiation, malignancy risk, serious hypersensitivity, and advice about live vaccines.
If you or someone you care for is considering or using PYZCHIVA, the label emphasizes evaluating for latent TB before starting treatment and stopping the drug if a serious infection develops. The label also notes reports of noninfectious pneumonia and other post-marketing adverse events observed with ustekinumab products.
This entry reflects the FDA drug-label update as posted on DailyMed and summarizes indications and key safety precautions from that label. It is not medical advice; specific questions about use, eligibility, monitoring, or side-effect management should be discussed with a prescribing clinician.
Keep In Mind
This is an FDA drug-label (regulatory-record) update posted on DailyMed summarizing approved indications and labeled warnings. It does not present new clinical-trial results; it reflects approved prescribing information and known class safety concerns for IL-12/23 inhibitors (ustekinumab products).
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorSANDOZ INC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 9, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ustekinumab FDA label update (2026-06-19)
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
Teva jumps on FDA approval for biosimilar
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...